A5044094148- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Treatment and Management
- Pharmaceutical Economics and Policy
- Economic and Environmental Valuation
- Statistical Methods in Clinical Trials
- Pancreatic and Hepatic Oncology Research
- Advanced Causal Inference Techniques
- Medication Adherence and Compliance
- Diabetes Management and Research
- Pharmaceutical industry and healthcare
- Lung Cancer Treatments and Mutations
- Healthcare Policy and Management
- Pharmaceutical studies and practices
- Metabolism, Diabetes, and Cancer
- Neuroendocrine Tumor Research Advances
- Herpesvirus Infections and Treatments
- Pharmacovigilance and Adverse Drug Reactions
- Lung Cancer Diagnosis and Treatment
- Chronic Disease Management Strategies
- Bartonella species infections research
- Meta-analysis and systematic reviews
- Decision-Making and Behavioral Economics
- Blood Pressure and Hypertension Studies
- Heart Failure Treatment and Management
- Ethics in Clinical Research
Medidata (United States)
2023-2025
Brigham and Women's Hospital
2015-2024
Harvard University
2015-2024
University of Science and Technology of Mazandaran
2022
Boehringer Ingelheim (Germany)
2019
St. John's University
2018
CVS Health (United States)
2015
Massachusetts General Hospital
2013-2015
University of British Columbia
2006-2014
Centre for Health Evaluation and Outcome Sciences
2008-2013
Background: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. Objective: To evaluate the cost-effectiveness these treatments under different assumptions about their price efficacy. Design: Discrete-event simulation. Data Sources: Published literature. Target Population: Treatment-naive patients infected chronic HCV genotype 1, 2, or 3. Time Horizon:...
The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces the risk of hospitalization for heart failure (HHF) by 35%, on top standard care patients with type mellitus (T2D) and established cardiovascular disease. EMPRISE Comparative Effectiveness Safety) study aims to assess empagliflozin's effectiveness, safety, healthcare utilization routine from August...
Cognition is a multidimensional construct and to our knowledge, no previous studies have examined the independent contribution of specific domains cognition health related quality life. To determine whether executive functions are independently associated with life assessed using Quality Adjusted Life Years (QALYs) calculated from EuroQol EQ-5D (EQ-5D) in older women after adjusting for known covariates, including global cognition. Therefore, we conducted secondary analysis...
Recent studies have shown an increasing incidence of herpes zoster (HZ) infection, which may be related to the introduction varicella vaccination programs in children. We examined epidemiology and treatment costs HZ post-herpetic neuralgia (PHN) over time British Columbia, Canada. The cohort consisted all cases with infection from January 1, 1997 December 31, 2012. Incident was defined as a case (ICD-9 053 or ICD-10 B02) without previous episode PHN 12 months. determined for age-sex...
Current recommendations of The US Preventive Services Task Force (USPSTF) on colorectal cancer (CRC) screening strategies are based models that assume 100% adherence. Since adherence can have a large effect outcomes, we aimed to compare the effectiveness CRC under reported rates at population level. We developed and validated microsimulation model assess colonoscopy (COL), flexible sigmoidoscopy (FS), high-sensitivity guaiac fecal occult blood-test (HS-gFOBT), immunochemical test (FIT),...
Abstract Aim To investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin versus dipeptidyl peptidase‐4 (DPP‐4) inhibitor treatment across the broad spectrum of cardiovascular risk. Methods In a population‐based cohort study we identified 39 072 pairs 1:1 propensity score‐matched adult T2D or DPP‐4 inhibitors, using data from US commercial insurance databases Medicare between August 2014 September 2017. The primary were composite...
Limited evidence is available on the comparative effectiveness of empagliflozin vs alternative second-line glucose-lowering agents in patients with type 2 diabetes (T2D) receiving routine care who have a broad spectrum cardiorenal risk.To evaluate association cardiovascular outcomes relative to liraglutide and sitagliptin, stratified by age, sex, baseline atherosclerotic disease (ASCVD), heart failure (HF), chronic kidney (CKD).This retrospective cohort study used deidentified Medicare...
Importance Patients who participate in clinical trials generate valuable routinely collected data (eg, medical records, electronic health claims databases, disease registries, or vital statistics) through their routine interactions with the care system before, during, and after trial. When this is linked at participant level, it can supplement active collection trial provide deeper insights into benefits, risks, costs of treatments. Objective To review to various countries, identifying use...
<h3>Background:</h3> Little is known about the combination of different medications in chronic obstructive pulmonary disease (COPD). This study determined cost effectiveness adding salmeterol (S) or fluticasone/salmeterol (FS) to tiotropium (T) for COPD. <h3>Methods:</h3> concurrent, prospective, economic analysis was based on costs and health outcomes from a 52 week randomised comparing: (1) T 18 µg once daily + placebo twice (TP group); (2) S 25 µg/puff, 2 puffs (TS (3) FS 250/25 (TFS...
One difficulty in translating clinical trial findings for target patient populations is that risk factors trials and electronic health care databases are measured different ways. We therefore need a way to calibrate our measurements between these two data worlds.
Background Chronic obstructive pulmonary disease (COPD) is a growing economic burden worldwide. Smoking cessation thought to be the single most effective way of reducing COPD. The impact other strategies such as interventions that predict risk disease, reduce progression or exacerbations has not been systematically studied. Objectives We estimated and clinical COPD over next 25 years in Canada three potential (screening test for predisposition COPD, new drugs avoid into more severe stages,...
ObjectiveFine-needle aspiration biopsy (FNAB) is a safe and inexpensive diagnostic procedure for evaluating thyroid nodules.Up to 25% of the results from an FNAB, however, may not be or indeterminate, leading subsequent surgery. A new molecularly based test could potentially reduce indeterminate cytological and, with high accuracy, provide definitive diagnosis cancer in nodules. The aim study was estimate cost-effectiveness utilizing molecular (DX) as adjunct compared NoDX, improve...
Abstract Personalized medicine—tailoring interventions based on individual's genetic information—will likely change routine clinical practice in the future. Yet, how practitioners plan to apply information inform medical decision making remains unclear. We aimed investigate physician's perception about future role of personalized medicine, and identify factors that influence their using testing practice. conducted three semi‐structured focus groups health regions (Fraser, Vancouver coastal,...
Many of the quality measures used to assess accountable care organization (ACO) performance in Medicare Shared Savings Program (MSSP) focus on disease control and medication use among patients with cardiovascular diabetes. To date, association between participation MSSP by provider organizations or adherence their diabetes has not been described.To exposure changes common antihypertensive, lipid-lowering, hypoglycemic medications.Fee-for-service claims from January 1, 2009, December 31,...
Abstract Background The EMPA‐REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with disease. EMPRISE is a study programme on effectiveness, safety healthcare utilization routine care, leveraging real‐world data from two commercial one federal US sources 2014 to 2019. Objectives To describe rationale design EMPRISE, assess ability minimize confounding evaluate time reach sufficient statistical...